These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 29177689

  • 21. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F, Dieci MV, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, Guarneri V.
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [Abstract] [Full Text] [Related]

  • 22. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
    Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E.
    Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175
    [Abstract] [Full Text] [Related]

  • 23. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
    Salim DK, Mutlu H, Eryilmaz MK, Musri FY, Tural D, Gunduz S, Coskun HS.
    Asian Pac J Cancer Prev; 2014 Jun; 15(21):9379-83. PubMed ID: 25422228
    [Abstract] [Full Text] [Related]

  • 24. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L, Pistelli M, Merloni F, Fontana A, Bertolini I, De Angelis C, Bastianelli L, Della Mora A, Santinelli A, Savini A, Maccaroni E, Diodati L, Falcone A, Berardi R.
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [Abstract] [Full Text] [Related]

  • 25. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F, Ma L, Geng C, Liu C, Deng H, Yue M, Ding Y, Wang X, Liu Y.
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [Abstract] [Full Text] [Related]

  • 26. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP, Peer A, Weismann C, Meissnitzer M, Rinnerthaler G, Webhofer J, Westphal T, Riedmann M, Meissnitzer T, Egger H, Klaassen Federspiel F, Reitsamer R, Hauser-Kronberger C, Stering K, Hergan K, Mlineritsch B, Greil R.
    Breast Cancer Res; 2019 Jan 31; 21(1):19. PubMed ID: 30704493
    [Abstract] [Full Text] [Related]

  • 27. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y, Sim SH, Park B, Lee KS, Chae IH, Park IH, Kwon Y, Jung SY, Lee S, Ko K, Kang HS, Lee CW, Lee ES.
    Clin Breast Cancer; 2018 Dec 31; 18(6):459-467.e1. PubMed ID: 29954674
    [Abstract] [Full Text] [Related]

  • 28. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
    Zentralbl Gynakol; 2006 Apr 31; 128(2):76-81. PubMed ID: 16673249
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H, Wagner S, Flake DD, Robson M, Schwartzberg L, Sharma P, Magliocco A, Kronenwett R, Lancaster JM, Lanchbury JS, Gutin A, Gradishar W.
    Ann Surg Oncol; 2020 Mar 31; 27(3):765-771. PubMed ID: 31907749
    [Abstract] [Full Text] [Related]

  • 30. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer HU, Fasching PA, Weber KE, Albig C, Heinrichs C, Marmé F, Hartmann A, Hanusch C, Schmitt WD, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn BV, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Loibl S.
    Eur J Cancer; 2021 May 31; 148():159-170. PubMed ID: 33743484
    [Abstract] [Full Text] [Related]

  • 31. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM.
    Ann Surg Oncol; 2012 Sep 31; 19(9):3002-11. PubMed ID: 22437200
    [Abstract] [Full Text] [Related]

  • 32. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.
    Breast; 2014 Aug 31; 23(4):466-72. PubMed ID: 24742606
    [Abstract] [Full Text] [Related]

  • 33. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M.
    Eur J Surg Oncol; 2013 Oct 31; 39(10):1046-52. PubMed ID: 23890870
    [Abstract] [Full Text] [Related]

  • 34. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, Parodi MA, Morabito F.
    Oncology; 2010 Oct 31; 79(3-4):255-61. PubMed ID: 21372600
    [Abstract] [Full Text] [Related]

  • 35. PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study.
    Miglietta F, Carraro V, Amato O, Griguolo G, Bottosso M, Munari G, Zarrilli G, Lo Mele M, Barbieri C, Dei Tos AP, Guarneri V, Dieci MV, Fassan M.
    J Clin Pathol; 2024 Sep 19; 77(10):690-696. PubMed ID: 37344170
    [Abstract] [Full Text] [Related]

  • 36. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
    Enomoto Y, Morimoto T, Nishimukai A, Higuchi T, Yanai A, Miyagawa Y, Murase K, Imamura M, Takatsuka Y, Nomura T, Takeda M, Watanabe T, Hirota S, Miyoshi Y.
    Int J Clin Oncol; 2016 Apr 19; 21(2):254-261. PubMed ID: 26338270
    [Abstract] [Full Text] [Related]

  • 37. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW, Jung H, Hyeon J, Park YH, Ahn JS, Im YH, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Choi M, Cho SY, Cho EY.
    Breast Cancer Res Treat; 2019 Jan 19; 173(2):255-266. PubMed ID: 30324273
    [Abstract] [Full Text] [Related]

  • 38. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, Karn T, Taube ET, Klauschen F, Marmé F, Schem C, Stickeler E, Ataseven B, Huober J, von Minckwitz G, Seliger B, Denkert C, Loibl S.
    Breast Cancer Res; 2019 Dec 11; 21(1):142. PubMed ID: 31829264
    [Abstract] [Full Text] [Related]

  • 39. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
    Muñoz-Montaño W, Cabrera-Galeana P, Alvarado-Miranda A, Villarreal-Garza C, Mohar A, Olvera A, Bargallo-Rocha E, Lara-Medina F, Arrieta O.
    Clin Breast Cancer; 2020 Aug 11; 20(4):307-316.e1. PubMed ID: 32305297
    [Abstract] [Full Text] [Related]

  • 40. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor.
    Loibl S, Weber K, Huober J, Krappmann K, Marmé F, Schem C, Engels K, Pfitzner BM, Kümmel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Müller V, Staebler A, von Minckwitz G, Kronenwett R, Denkert C.
    Clin Cancer Res; 2018 Jul 15; 24(14):3358-3365. PubMed ID: 29618617
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.